A randomized, double-blind, study of ruxolitinib or placebo in combination with capecitabine as second line treatent for Subjects With Pancreatic cancer (The JANUS 1 Study)

Update Il y a 4 ans
Reference: EUCTR2014-000293-20

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate and compare the OS of subjects with advanced or metastatic adenocarcinoma of the pancreas when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.


Inclusion criteria

  • Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic